EMA — authorised 19 September 2024
- Application: EMEA/H/C/006206
- Marketing authorisation holder: Accord Healthcare S.L.U.
- Local brand name: Axitinib Accord
- Indication: Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
- Status: approved
The European Medicines Agency (EMA) granted marketing authorisation for Axitinib Accord (AG-103736) on 19 September 2024. Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. This authorisation was granted to Accord Healthcare S.L.U. as the marketing authorisation holder.